During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.
During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research. Various clinical issues faced while treating melanoma patients, including the optimal combination therapies and disease resistance to therapies, were discussed. Scientists also presented data and created a case for novel drug therapies in melanoma.
One of these presentations was by Janice Mehnert, MD, medical oncologist and interim director of the Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey. Her presentation, “Atg7 overcomes senescence and promotes growth of BRAF-driven melanoma,” evauated Atg7 as a novel target in the treatment of B-Raf-mutated melanoma patient. Atg7 plays an important role in cell autophagy, and knockdown of this gene was shown to sensitize B-Raf wild type cells to death. This indicates a pro-survival role for autophagy in melanoma.
The process of cellular autophagy has several signaling pathways and components. Autophagy enables tumors to survive metabolic stress by recycling intracellular components to sustain metabolism. When the authors knocked down 2 of the components, Atg5 and Atg7, it impaired cell growth in multiple melanoma cell lines, demonstrating that these cancer cells depend on autophagy for their survival. There is a difference in cell sensitivity to Atg5 versus Atg7, indicating that some tumors rely more heavily on certain components of the pathway than others.
To test their hypothesis that inhibition of autophagy would enhance melanoma cell death, the authors used a genetically engineered mouse model with activated BRAFV600E and Pten-knockout in melanocytes. Atg7 loss in these mice prevented melanoma development by BRAFV600E and allelic Pten loss, suggesting that ATG7 and autophagy promote melanoma. Atg7 loss reduced melanoma growth and extended animal survival by 50%. Tumors with Atg7 loss accumulated LC3-I, p62, and abnormal mitochondria characteristic of autophagy defect. Next, the authors examined the role of Atg7 in senescence, a known barrier to melanoma. Atg7-deficient tumors were positive for senescence marker, consistent with upregulation of senescence. This in turn correlated with the induction of γ-H2X and 8-OXO-DG, markers of elevated oxidative stress. Dr Mehnert concluded that Atg7 promotes the growth of BRAFV600E- and Pten-null driven melanomas by limiting oxidative stress and overcoming the senescence barrier, and that autophagy inhibition may be of therapeutic value in the treatment of melanoma patients.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More